Your browser doesn't support javascript.
loading
Clozapine and Sweet's syndrome: case report.
Bunting, Apphia; Silman, Daniel; Karia, Minesh; Johnson, Sophie.
Afiliação
  • Bunting A; Oxford Health Foundation Trust, Warneford Hospital, Oxford, UK.
  • Silman D; Oxford Health NHS Foundation Trust, Oxford, UK.
  • Karia M; Oxford Health NHS Foundation Trust, Oxford, UK.
  • Johnson S; Oxford Health NHS Foundation Trust, Oxford, UK.
BJPsych Open ; 9(5): e166, 2023 Sep 04.
Article em En | MEDLINE | ID: mdl-37665047
ABSTRACT
A patient developed fever, raised inflammatory markers and a maculopapular rash following commencement of clozapine for treatment of his schizoaffective disorder. Skin biopsy confirmed Sweet's syndrome. Identification of the cause was challenging, with a number of possible considerations including infection, malignancy and various potential drug triggers.This case highlights the difficulties in the diagnosis of Sweet's syndrome, as well as in identifying the original trigger, which can have significant consequences for management. Withdrawal of potentially causative drugs must be balanced with their benefits, and decisions must be made in the best interests of the patient. Following two courses of prednisolone and withdrawal of clozapine, the patient's rash and systemic symptoms resolved. This confirmed the diagnosis of drug-induced Sweet's syndrome, with clozapine as the offending agent. His mental state stabilised on an alternative antipsychotic.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido